Oruka Therapeutics, Inc.
ORKANasdaq
$92.70
↑ +11.6%Jul 17 close · end-of-day
Price
1Y↑ +526.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$116.3M
Free Cash Flow (TTM)
-$91.2M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-23.9%
ROIC
-107.7%
Debt / Equity
—
Net Cash
$388.8M
Return 1Y
+503.5%
Company profile
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Our mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases.
- CEO
- Lawrence Klein
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- ir.orukatx.com
Management & directors
- Goncalves JoanaChief Medical Officer
- Agarwal ArjunSenior Vice President, Finance
- Sandler Laura LeeChief Operating Officer
- Klein Lawrence OttoChief Executive Officer
- Quinlan Paul TGeneral Counsel
Roles derived from SEC Form 4 filings.
Earnings
ORKA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.8M | -$19.3M | -$10.6M | -$7.3M | — | -$122.1M |
| Net income | -$9.7M | -$19.3M | -$9.9M | -$5.3M | -$83.7M | -$105.4M |
| Diluted EPS | — | -$1.39 | -$0.69 | -$0.37 | — | — |
| Operating cash flow | -$7.7M | -$18.8M | -$10.9M | -$5.0M | — | -$88.2M |
| Free cash flow | -$7.7M | -$18.8M | -$10.9M | -$5.0M | — | -$88.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$21.5M | -$29.4M | — | -$25.1M | -$28.4M | -$34.1M | -$34.4M | -$36.4M |
| Net income | -$22.2M | -$28.6M | -$30.8M | -$21.0M | -$24.6M | -$30.3M | -$29.6M | -$31.8M |
| Diluted EPS | -$6.96 | -$1.46 | — | -$0.40 | -$0.46 | — | — | — |
| Operating cash flow | -$2.6M | — | — | -$20.9M | -$23.1M | -$21.6M | -$22.6M | -$23.6M |
| Free cash flow | — | — | — | -$20.9M | -$23.2M | -$21.7M | -$22.7M | -$23.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Goncalves Joana· Chief Medical Officer | Sale | 3,803 | $86.68 | $329,630.35 | filing |
| 2026-07-15 | Goncalves Joana· Chief Medical Officer | Sale | 2,497 | $85.86 | $214,385.43 | filing |
| 2026-07-15 | Goncalves Joana· Chief Medical Officer | Sale | 400 | $84.37 | $33,746.00 | filing |
| 2026-07-15 | Goncalves Joana· Chief Medical Officer | Option exercise | 3,500 | $7.80 | $27,300.00 | filing |
| 2026-07-15 | Goncalves Joana· Chief Medical Officer | Sale | 300 | $87.25 | $26,175.99 | filing |
| 2026-07-15 | Goncalves Joana· Chief Medical Officer | Option exercise | 3,500 | $6.84 | $23,940.00 | filing |
| 2026-07-13 | Agarwal Arjun· Senior Vice President, Finance | Sale | 5,656 | $84.90 | $480,201.19 | filing |
| 2026-07-13 | Agarwal Arjun· Senior Vice President, Finance | Sale | 3,743 | $84.26 | $315,369.09 | filing |
| 2026-07-13 | Agarwal Arjun· Senior Vice President, Finance | Option exercise | 8,541 | $12.50 | $106,762.50 | filing |
| 2026-07-13 | Agarwal Arjun· Senior Vice President, Finance | Option exercise | 1,458 | $34.39 | $50,140.62 | filing |
| 2026-07-13 | Agarwal Arjun· Senior Vice President, Finance | Sale | 300 | $85.63 | $25,689.99 | filing |
| 2026-07-13 | Agarwal Arjun· Senior Vice President, Finance | Sale | 300 | $83.07 | $24,919.95 | filing |
| 2026-07-01 | Fairmount Funds Management LLC | Sale | 3,553,410 | $84.43 | $300.0M | filing |
| 2026-07-01 | Sandler Laura Lee· Chief Operating Officer | Sale | 2,263 | $94.75 | $214,409.75 | filing |
| 2026-07-01 | Sandler Laura Lee· Chief Operating Officer | Sale | 2,237 | $93.85 | $209,932.83 | filing |
| 2026-07-01 | Sandler Laura Lee· Chief Operating Officer | Sale | 500 | $95.47 | $47,736.00 | filing |
| 2026-07-01 | Sandler Laura Lee· Chief Operating Officer | Option exercise | 5,000 | $7.80 | $39,000.00 | filing |
| 2026-07-01 | Fairmount Funds Management LLC | C | 3,553,410 | — | — | filing |
| 2026-06-22 | Agarwal Arjun· Senior Vice President, Finance | Sale | 888 | $80.01 | $71,048.88 | filing |
| 2026-06-22 | Agarwal Arjun· Senior Vice President, Finance | Sale | 699 | $82.15 | $57,419.36 | filing |
| 2026-06-15 | Goncalves Joana· Chief Medical Officer | Sale | 5,064 | $69.42 | $351,547.44 | filing |
| 2026-06-15 | Klein Lawrence Otto· Chief Executive Officer | Sale | 1,729 | $69.69 | $120,494.01 | filing |
| 2026-06-15 | Goncalves Joana· Chief Medical Officer | Sale | 1,636 | $68.38 | $111,876.06 | filing |
| 2026-06-15 | Goncalves Joana· Chief Medical Officer | Sale | 947 | $69.69 | $65,996.43 | filing |
| 2026-06-15 | Quinlan Paul T· General Counsel | Sale | 733 | $69.69 | $51,082.77 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.